Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors

Hematology/Oncology Clinics of North America

Volumn 26, Issue 4, 2012, Pages 757-777

  Patel, Toral R ^a   Yu, James B ^a   Piepmeier, Joseph M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Primary brain tumors; Prognosis; Radiation; Surgery; Treatment

Indexed keywords

CORTICOSTEROID; CYTARABINE; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; VINCRISTINE;

ACOUSTIC NEURINOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CANCER THERAPY; CHILDHOOD CANCER; CRANIAL NEUROPATHY; EPENDYMOMA; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HEAVY ION RADIATION; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS TUMOR; LIQUORRHEA; MEDICAL RESEARCH; MENINGIOMA; NEUROSURGERY; OLIGODENDROGLIOMA; PINEAL BODY TUMOR; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

BRAIN; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS;

EID: 84863878859     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.04.001     Document Type: Review

References (79)

1. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
2. Preusser M., de Ribaupierre S., Wohrer A., et al. Current concepts and management of glioblastoma. Ann Neurol 2011, 70:9-21.
3. Sanai N., Berger M.S. Intraoperative stimulation techniques for functional pathway preservation and glioma resection. Neurosurg Focus 2010, 28:E1.
4. Laws E.R., Parney I.F., Huang W., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003, 99:467-473.
5. Stummer W., van den Bent M.J., Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011, 153:1211-1218.
6. Sanai N., Polley M.Y., McDermott M.W., et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115:3-8.
7. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol 1999, 42:303-305.
8. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
9. Simpson J.R., Horton J., Scott C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993, 26:239-244.
10. Stummer W., Pichlmeier U., Meinel T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
11. Senft C., Bink A., Franz K., et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011, 12:997-1003.
12. Pouratian N., Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep 2010, 10:224-231.
13. van den Bent M.J., Wefel J.S., Schiff D., et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011, 12:583-593.
14. Smith J.S., Chang E.F., Lamborn K.R., et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008, 26:1338-1345.
15. McGirt M.J., Chaichana K.L., Attenello F.J., et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008, 63:700-707. [author reply: 707-8].
16. Gilbert M.R., Ruda R., Soffietti R. Ependymomas in adults. Curr Neurol Neurosci Rep 2010, 10:240-247.
17. Niazi T.N., Jensen E.M., Jensen R.L. WHO grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options. J Neurooncol 2009, 91:323-328.
18. Metellus P., Barrie M., Figarella-Branger D., et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007, 130:1338-1349.
19. Kawabata Y., Takahashi J.A., Arakawa Y., et al. Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 2005, 103:31-37.
20. Schwartz T.H., Kim S., Glick R.S., et al. Supratentorial ependymomas in adult patients. Neurosurgery 1999, 44:721-731.
21. Paulino A.C., Wen B.C., Buatti J.M., et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 2002, 25:117-122.
22. Konovalov A.N., Pitskhelauri D.I. Principles of treatment of the pineal region tumors. Surg Neurol 2003, 59:250-268.
23. Gerstner E.R., Batchelor T.T. Primary central nervous system lymphoma. Arch Neurol 2010, 67:291-297.
24. Morris P.G., Abrey L.E. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009, 8:581-592.
25. Oya S., Kim S.H., Sade B., et al. The natural history of intracranial meningiomas. J Neurosurg 2011, 114:1250-1256.
26. Sughrue M.E., Rutkowski M.J., Aranda D., et al. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg 2010, 113:1036-1042.
27. Arthurs B.J., Fairbanks R.K., Demakas J.J., et al. A review of treatment modalities for vestibular schwannoma. Neurosurg Rev 2011, 34:265-277. [discussion: 277-9].
28. Quant E.C., Wen P.Y. Response assessment in neuro-oncology. Curr Oncol Rep 2011, 13:50-56.
29. Winder M.J., Mayberg M.R. Recent advances in pituitary tumor management. Curr Opin Endocrinol Diabetes Obes 2011, 18:278-288.
30. Strychowsky J., Nayan S., Reddy K., et al. Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review. J Otolaryngol Head Neck Surg 2011, 40:175-185.
31. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
32. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
33. Amelio D., Lorentini S., Schwarz M., et al. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol 2010, 97:361-369.
34. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
35. van Nifterik K.A., van den Berg J., Stalpers L.J., et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007, 69:1246-1253.
36. Martin M. Laser accelerated radiotherapy: is it on its way to the clinic?. J Natl Cancer Inst 2009, 101:450-451.
37. Combs S.E., Burkholder I., Edler L., et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer 2010, 10:533.
38. Combs S.E., Kieser M., Rieken S., et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer 2010, 10:478.
39. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
40. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
41. Cho K.H., Kim J.Y., Lee S.H., et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 2010, 78:390-397.
42. McDonald M.W., Shu H.K., Curran W.J., et al. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011, 79:130-136.
43. Gilbert M.R., Lang F.F. Anaplastic oligodendroglial tumors: a tale of two trials. J Clin Oncol 2006, 24:2689-2690.
44. Vogelbaum M.A., Berkey B., Peereboom D., et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 2009, 11:167-175.
45. Gan H.K., Rosenthal M.A., Dowling A., et al. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol 2010, 12:500-507.
46. Wick W., Hartmann C., Engel C., et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880.
47. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985-990.
48. Douw L., Klein M., Fagel S.S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8:810-818.
49. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002, 20:2267-2276.
50. Kiebert G.M., Curran D., Aaronson N.K., et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 1998, 34:1902-1909.
51. Leighton C., Fisher B., Macdonald D., et al. The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J Neurooncol 2007, 82:165-170.
52. Minniti G., Armosini V., Salvati M., et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 2011, 103:683-691.
53. Torok J.A., Wegner R.E., Mintz A.H., et al. Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 2011, 10:253-258.
54. Fogh S.E., Andrews D.W., Glass J., et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010, 28:3048-3053.
55. Combs S.E., Thilmann C., Edler L., et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005, 23:8863-8869.
56. Nieder C., Astner S.T., Mehta M.P., et al. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008, 31:300-305.
57. Kong D.S., Lee J.I., Park K., et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 2008, 112:2046-2051.
58. Kano H., Niranjan A., Kondziolka D., et al. Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery 2009, 64:279-287. [discussion: 287-8].
59. Chen Y.W., Huang P.I., Ho D.M., et al. Change in treatment strategy for intracranial germinoma: long-term follow-up experience at a single institute. Cancer 2011, [Epub ahead of print]. 10.1002/cncr.26564.
60. Montemurro M., Kiefer T., Schuler F., et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007, 18:665-671.
61. Colombat P., Lemevel A., Bertrand P., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006, 38:417-420.
62. Schultz C.J., Bovi J. Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 2010, 76:666-678.
63. Kondziolka D., Madhok R., Lunsford L.D., et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg 2009, 111:458-463.
64. Roos D.E., Potter A.E., Brophy B.P. Stereotactic radiosurgery for acoustic neuromas: what happens long term?. Int J Radiat Oncol Biol Phys 2012, 82(4):1352-1355.
65. Loeffler J.S., Shih H.A. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011, 96(7):1992-2003.
66. Kong D.S., Lee J.I., Lim do H., et al. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer 2007, 110:854-860.
67. Estall V., Treece S.J., Jena R., et al. Pattern of relapse after fractionated external beam radiotherapy for meningioma: experience from Addenbrooke's Hospital. Clin Oncol (R Coll Radiol) 2009, 21:745-752.
68. Andrews D.W., Suarez O., Goldman H.W., et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. Int J Radiat Oncol Biol Phys 2001, 50:1265-1278.
69. Meijer O.W., Vandertop W.P., Baayen J.C., et al. Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. Int J Radiat Oncol Biol Phys 2003, 56:1390-1396.
70. Collen C., Ampe B., Gevaert T., et al. Single fraction versus fractionated linac-based stereotactic radiotherapy for vestibular schwannoma: a single-institution experience. Int J Radiat Oncol Biol Phys 2011, 81:e503-e509.
71. Timmer F.C., Hanssens P.E., van Haren A.E., et al. Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose. Laryngoscope 2009, 119:1076-1081.
72. Kano H., Kondziolka D., Khan A., et al. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma. J Neurosurg 2009, 111:863-873.
73. Gerosa M., Mesiano N., Longhi M., et al. Gamma Knife surgery in vestibular schwannomas: impact on the anterior and posterior labyrinth. J Neurosurg 2010, 113(Suppl):128-135.
74. Pollock B.E. Comparing radiation therapy and radiosurgery for pituitary adenoma patients. World Neurosurg 2011, in press.
75. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
76. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
77. Kocher M., Soffietti R., Abacioglu U., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141.
78. Pollack I.F. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011, 8:135-148.
79. Patel T., Zhou J., Piepmeier J.M., et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 2012, 64(7):701-705.